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Implantable cardioverter-deﬁbrillators (ICDs) are devices
that are implanted in patients who are at risk for sudden
cardiac death due to potential fatal arrhythmias such
as ventricular ﬁbrillation or ventricular tachycardia.1,2
Although potentially lifesaving, ICD systems (pulse gener-
ator and leads) are subject to both mechanical and electrical
faults.3,4 In particular, electromagnetic energy can cause
varying levels of interference with these devices.5–8Figure 1 Chest x-ray ﬁlm, anteroposterior view, showing the relative
position of the implantable cardioverter-deﬁbrillator and breast tissue expander.Case report
A 53- year-old woman with a history of right-sided breast
cancer diagnosed 11 years ago developed a recurrence at the
same site 1 year prior to admission (PTA). After recurrence,
she underwent right mastectomy, followed by placement of a
breast tissue expander (BTE; Dermaspan Low Pole
Expander, Surgical Specialty Products Inc, Victor, MT)
and chemotherapy. A few months later, a prophylactic left
mastectomy was performed, followed by placement of a
similar BTE with plans to undergo a simultaneous bilateral
second-stage breast reconstruction with implant exchange
and revision in about 6 months, per usual practice. Three
months PTA, she presented with shortness of breath and ﬂuid
overload. She was found to have a severe dilated cardiomy-
opathy with an ejection fraction of 15%. This was believed to
be most consistent with a chemotherapy-induced cardiomy-
opathy. One month PTA, a single-chamber ICD (Medtronic
Evera XT VR, Medtronic Corp, Minneapolis, MN) was
implanted in the left infraclavicular position after multiple
sudden syncopal episodes and recurrent runs of nonsustainedFigure 2 Chest x-ray ﬁlm, lateral view, showing the relative position of
the implantable cardioverter-deﬁbrillator and breast tissue expander.
KEYWORDS Breast tissue expander; Implantable cardioverter-deﬁbrillator;
Magnetic injection port; Interaction; Magnet mode conversion
ABBREVIATIONS BTE ¼ breast tissue expander; ICD ¼ implantable
cardioverter-defibrillator; PTA ¼ prior to admission
(Heart Rhythm Case Reports 2015;1:167–168)
Address reprint requests and correspondence: Dr. Malik Muhammad
Khurram Sher Khan, 1000 Monroe Ave NW, Grand Rapids, MI 49503.
E-mail address: khurramsher86@gmail.com.
2214-0271 B 2015 Heart Rhythm Society. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). http://dx.doi.org/10.1016/j.hrcr.2015.01.005
KEY TEACHING POINTS
 Electromagnetic energy can cause varying levels of
interference with implantable cardioverter-
deﬁbrillators (ICDs).
 There can be a potentially dangerous interaction of
interference between a magnetic injection port
locator in a breast tissue expander (BTE) and an
ICD. This interaction may be difﬁcult, if not
impossible, to recognize at the time of implant
because it may not occur with the patient in the
supine position.
 Because ICDs provide lifesaving therapy, it is
imperative that patients who have BTEs with
magnetic ports be switched to the
nonmagnetic type.
 Patients should undergo prompt ICD interrogation
whenever the device emits an unusual tone.
Heart Rhythm Case Reports, Vol 1, No 4, July 2015168ventricular tachycardia. At the time of implantation, a
subcutaneous ICD was not available at our institution or in
our region. She was not compliant in taking her heart failure
medications and was admitted to the hospital with signs and
symptoms of anasarca, severe exertional dyspnea, and
orthopnea. A diagnosis of acute-on-chronic biventricular
heart failure was made. She also had complaints for at least 3
weeks of a peculiar high-pitched sound that lasted for few
seconds coming from the left side of her chest whenever she
leaned forward or raised her left arm. ICD interrogation
revealed all functions were within normal limits, and no
alerts or sustained arrhythmias were noted. However, when
the programmer head was placed over her device, the sound
she had been hearing was reproduced exactly. The sound is
the magnet tone of her ICD. The magnetic injection port
in her BTE was determined to be interacting with her ICD
when she leaned forward or moved her arm (Figures 1 and 2).
Both movements brought her BTE and ICD in closer
proximity to one another, causing a magnet mode conversion
tone. When this occurred, the device not only toned, butall antitachycardia therapies (antitachycardia pacing and
shocks) were temporarily suspended.
Ultimately, after initial postponing her second-stage
reconstruction due to her heart failure, her BTEs were
replaced with silicone implants after optimization of her
cardiac status. She was subsequently transferred to a long-
term acute care hospital for further rehabilitation.
Discussion
This case demonstrates a potentially dangerous interaction of
interference between a magnetic injection port locator in a
breast tissue expander and an ICD. Because this interaction
did not occur when the patient was in the supine position, it
may be difﬁcult, if not impossible, to recognize this event at
the time of implant. Because ICDs provide lifesaving
therapy, it is imperative that patients who have BTEs with
magnetic ports be switched to the nonmagnetic type. In
addition, patients should undergo prompt ICD interrogation
whenever the device emits an unusual tone.
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